Acurx Pharmaceuticals, Inc. filed a Current Report on Form 8-K with the Securities and Exchange Commission on October 29, 2026, announcing an amendment to its corporate bylaws. The amendment was approved and adopted by the Company's Board of Directors on that same date.
The primary change involves the requirement for a quorum at meetings of the Company's stockholders. Previously, the Bylaws stipulated that a majority of all shares entitled to vote at a meeting, either present in person or by proxy, constituted a quorum. The newly adopted amendment lowers this threshold to one-third (33 1/3%) of the voting power of the outstanding stock entitled to vote at the meeting. This reduced quorum applies to meetings held in person, via remote communication, or by proxy, unless otherwise mandated by law or the Company's Certificate of Incorporation.
The filing includes a copy of the Amendment No. 1, which serves as the full text of the changes to the Bylaws. The report lists the amendment as Exhibit 3.1 to the filing.
